Regulation of macrophage gene expression by peroxisome-proliferator-activated receptor γ: Implications for cardiovascular disease

Current Opinion in Lipidology

Volumn 10, Issue 6, 1999, Pages 485-490

  Tontonoz, Peter ^a,c   Nagy, Laszlo ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; CD36 ANTIGEN; CELL NUCLEUS RECEPTOR; CYTOKINE; LIGAND; NITRIC OXIDE SYNTHASE; OXIDIZED LOW DENSITY LIPOPROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; ROSIGLITAZONE; TROGLITAZONE;

ARTERY WALL; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CELL DIFFERENTIATION; FOAM CELL; GENE EXPRESSION; GENE EXPRESSION REGULATION; LIPID METABOLISM; MACROPHAGE; PRIORITY JOURNAL; PROTEIN FAMILY; REVIEW; RISK; SIGNAL TRANSDUCTION;

ANIMALS; ARTERIOSCLEROSIS; CARDIOVASCULAR DISEASES; DNA-BINDING PROTEINS; FATTY ACIDS; GENE EXPRESSION REGULATION; HUMANS; HYPOGLYCEMIC AGENTS; MACROPHAGES; OXIDATION-REDUCTION; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SIGNAL TRANSDUCTION; THIAZOLES; TRANSCRIPTION FACTORS;

EUKARYOTA;

EID: 0033383563     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041433-199912000-00002     Document Type: Review

References (45)

1. Tontonoz P, Hu E, Spiegelman BM. Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor. Cell 1994; 79:1147-1156.
2. Spiegelman BM, Hu E, Kim JB, Brun R. PPAR gamma and the control of adipogenesis. Biochimie 1997; 79:111-112.
3. Mueller E, Sarraf P, Tontonoz P, Evans RM, Martin KJ, Zhang M, et al. Terminal differentiation of human breast cancer: expression and ligand activation of PPAR gamma. Mol Cell 1998; 1:465-70.
4. Sarraf P, Mueller E, Jones D, King FJ, DeAngelo DJ, Partridge JB, et al. Differentiation and reversal of malignant changes in colon cancer through PPAR gamma. Nat Med 1998; 4:1046-1052.
5. Braissant O, Foufelle F, Scotto C, Dauca M, Wahli W. Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology 1996; 137:354-366.
6. Greene ME, Blumberg B, McBride OW, Yi HF, Kronquist K, Kwan K, et al. Isolation of the human peroxisome proliferator activated receptor gamma cDNA:expression in hematopoietic cells and chromosomal mapping. Gene Express 1995; 4:281-299.
7. Kliewer SA, Umesono K, Noonan D, Heyman R, Evans RM. Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors. Nature 1992; 358:771-774.
8. Forman BM, Chen J, Evans RM. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proc Natl Acad Sci USA 1997; 94:4312-4317.
9. Kliewer SA, Sundseth SS, Jones SA, Brown PJ, Wisely GB, Koble CS, et al. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma. Proc Natl Acad Sci USA 1997; 94:4318-4323.
10. Nagy L, Tontonoz P, Alvarez JG, Chen H, Evans RM. Oxidized LDL regulates macrophage gene expression through ligand activation of PPAR gamma. Cell 1998; 93:229-240. •• This study reports that oxLDL can regulate gene expression through PPAR;gamma and that oxidized fatty acids are endogenous ligands for the receptor. Together with Tontonoz et al, [16••] it postulates a mechanism for the regulation of lipid uptake in foam cells.
11. Kliewer SA, Lenhard JM, Wilson TM, Patel I, Morris DC, Lehmann JM. A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation. Cell 1995; 83:813-819.
12. Forman BM, Tontonoz P, Chen J, Brun RP, Spiegelman BM, Evans RM. 15-Deoxy-delta 12,14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell 1995; 83:803-812.
13. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Wilson TM, Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for perosixome proliferator-activated receptor γ (PPARγ). J Biol Chem 1995; 270:12953-12956.
14. Kliewer SA, Forman BM, Blumberg B, Ong ES, Borgmeyer U, Mangelsdorf DJ, et al. Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc Natl Acad Sci USA 1994; 91:7355-7359.
15. Jiang C, Ting AT, Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 1998; 391:82-86. •• This study shows that PPARγ activators antagonize the expression of TNF-χ. IL-6 and IL1-β by activated human monocytes. It postulates that PPARγ activators may have anti-inflammatory activity.
16. Tontonoz P, Nagy L, Alvarez JG, Thomazy VA, Evans RM. PPAR gamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 1998; 93:241-252. •• This study reports the differentiation-dependent and oxLDL-regulated expression of PPARγ in macrophages. It identifies this receptor as a transcriptional regulator of CD36 expression and oxLDL uptake.
17. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 1998; 391:79-82. •• This study reports PPARγ expression in activated macrophages and that PPARγ activators inhibit the expression of SR-A and iNOS. It suggests that the role of PPARγ in macrophages is to antagonize activation-dependent gene expression.
18. Chinetti G, Griglio S, Antonucci M, Torra IP, Delerive P, Majd Z, et al. Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages. J Biol Chem 1998; 273:25573-25580. • This study reports the differentiation-dependent expression of PPARγ in monocytic cells and describes a potential role in apoptosis.
19. Huang JT, Welch JS, Ricote M, Binder CJ, Wilson TM, Kelly C, et al. Interleukin-4-dependent production of PPAR gamma ligands in macrophages by 12/15 lipoxygenase. Nature 1999; 400:378-382. •• This study provides evidence that oxidized fatty acids generated by 12/15 lipoxygenase activity (13-HODE and 15-HETE) may be important endogenous activators of PPARγ.
20. Ricote M, Huang J, Fajas L, Li A, Welch J, Najib J, et al. Expression of the peroxisome proliferator-activated receptor gamma (PPAR gamma) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Proc Natl Acad Sci USA 1998; 95:7614-7619. • This paper documents PPARγ expression in foam cells in human atherosclerotic lesions and reports its induction by granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor as well as oxLDL.
21. Marx N, Sukhova G, Murphy C, Libby P, Plutzky J. Macrophages in human atheroma contain PPAR gamma:differentiation-dependent peroxisomal proliferator-activated receptor gamma (PPAR gamma) expression and reduction of MMP-9 activity through PPAR gamma activation in mononuclear phagocytes in vitro. Am J Pathol 1998; 153:17-23. • This paper reports that PPARγ is expressed in foam cells in human atherosclerotic lesions and that the expression of MMP-9 is downregulated by PPARγ ligands.
22. Narumiya S, Fukushima M. Delta 12-prostaglandin J2, an ultimate metabolite of prostaglandin D2 exerting cell growth inhibition. Biochem Biophys Res Commun 1985; 127:739-745.
23. Narumiya S, Ohno K, Fukushima M, Fujiwara M. Site and mechanism of growth inhibition by prostaglandins. III. Distribution and binding of prostaglandin A2 and delta 12-prostaglandin J2 in nuclei. J Pharmacol Exp Ther 1987; 242:306-311.
24. Stary HC, Chandler AB, Glagov S, Guyton JR, Insull W, Rosenfeld ME, et al. A definition of initial, fatty streak and intermediate lesions of atherosclerosis: a report from the committee on vascular lesions of the council on arteriosclerosis, American Heart Association. Arterioscler Thromb 1994; 14:840-856.
25. Sanan DA, Newland DL, Tao R, Marcovina S, Wang J, Mooser V, et al. Low density lipoprotein receptor-negative mice expressing human apolipoprotein B-100 develop complex atherosclerotic lesions on a chow diet: no accentuation by apolipoprotein(a). Proc Natl Acad Sci USA 1998; 95:4544-4549.
26. Endemann G, Stanton LW, Madden KS, Bryant CM, White RT, Protter AA. CD36 is a receptor for oxidized low density lipoprotein. J Biol Chem 1993; 268:11811-11816.
27. Febbraio M, Abumrad NA, Hajjar DP, Sharma K, Cheng W, Pearce SF, Silverstein RL. A null mutation in murine CD36 reveals an important role in fatty acid and lipoprotein metabolism. J Biol Chem 1999; 274:19055-19062. •• This paper reports the interesting phenotype of the CD36 knockout mouse. In addition to confirming the importance of CD36 as a scavenger receptor the phenotype also implies an important role in lipid metabolism.
28. Nozaki S, Kashiwagi H, Yamashita S, Nakagawa T, Kostner B, Tomiyama Y, et al. Reduced uptake of oxidized low density lipoproteins in monocyte-derived macrophages from CD36-deficient subjects. J Clin Invest 1995; 96:1859-1865.
29. Steinberg D. Low density lipoprotein oxidation and its pathobiological significance. J Biol Chem 1997; 272:20963-20966.
30. Ku G, Thomas CE, Akeson AL, Jackson RL. Induction of interleukin 1 beta expression from human peripheral blood monocyte-derived macrophages by 9-hydroxyoctadecadienoic acid. J Biol Chem 1992; 267:14183-14188.
31. Harland WA, Gilbert JD, Steel G, Brooks CJ. Lipids of human atheroma. 5. The occurrence of a new group of polar sterol esters in various stages of human atherosclerosis. Atherosclerosis 1971; 13:239-246.
32. Kletzien RF, Foellmi LA, Harris PK, Wyse BM, Clarke SD. Adipocyte fatty acid-binding protein: regulation of gene expression in vivo and in vitro by an insulin-sensitizing agent. Mol Pharmacol 1992; 42:558-562.
33. Tontonoz P, Hu E, Graves RA, Budavari AI, Spiegelman BM. mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer. Genes Dev 1994; 8:1224-1234.
34. Ibrahimi A, Teboul L, Gaillard D, Amri EZ, Ailhaud G, Young P, Cawthorne MA, Grimaldi PA. Evidence for a common mechanism of action for fatty acids and thiazolidinedione antidiabetic agents on gene expression in preadipose cells. Mol Pharmacol 1994; 46:1070-1076.
35. Balfour JA, Plosker GL. Rosiglitazone. Drugs 1999; 57:921-930.
36. Nolan JJ, Ludvik B, Beerdsen P, Joyce M, Olefsky J. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med 1994; 331:1188-1193.
37. Maggs DG, Buchanan TA, Burant CF, Cline G, Gumbiner B, Hsueh WA, et al. Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1998; 128:176-185. • An important clinical trial documenting the metabolic of troglitazone in patients with type 2 diabetes.
38. Nozue T, Michishita I, Minagawa F, Genda A. Troglitazone directly increases HDL cholesterol levels. Diabetes Care 1999; 22:355-356.
39. Mori Y, Murakawa Y, Okada K, Horikoshi H, Yokoyama J, Tajima N, Ikeda Y. Effect of troglitazone on body fat distribution in type 2 diabetic patients. Diabetes Care 1999; 22:908-912.
40. Kelly I, Han T, Walsh K, Lean M. Effect of thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes. Diabetes Care 1999; 22:288-293.
41. Crawford R, Mudallar S, Henry R, Chait A. Inhibition of LDL oxidation in vitro but not ex vivo by troglitazone. Diabetes 1999; 48:783-790. • Describes the antioxidant effects of troglitazone.
42. Cominacini L, Garbin U, Fratta Pasini A, Campagnola M, Davoli A, Foot E, et al. Troglitazone reduces LDL oxidation and lowers plasma E-selectin concentration in NIDDM patients. Diabetes 1998; 47:130-133. • This study reports that troglitazone may have antioxidant effects in vivo.
43. Wang M, Wise SC, Leff T, Su TZ. Troglitazone, an antidiabetic agent, inhibits cholesterol biosynthesis through a mechanism independent of peroxisome proliferator-activated receptor-gamma. Diabetes 1999; 48:254-260. • This study reports an interesting effect of troglitazone on lipid metabolism not mediated by PPARγ.
44. Minamikawa J, Tanaka S, Yamauchi M, Inoue D, Koshiyama H. Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 1998; 83:1818-1820. • This paper presents evidence that troglitazone may protect against the development of atherosclerosis in humans.
45. Shiomi M, Ito T, Tsukada T, Tsujita Y, Horikoshi H. Combination treatment with troglitazone, an insulin action enhancer, and pravastatin, an inhibitor of HMG-CoA reductase, shows a synergistic effect on atherosclerosis of WHHL rabbits. Atherosclerosis 1999; 142:345-353. • Troglitazone can synergize with a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor to prevent atherosclerosis in hyperlipidemic rabbits.